Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olverembatinib vs standard therapy in TKI-resistant CML-CP
CTR20191420Phase 2Completed
- Sponsor
- Shunjian Biopharmaceutical
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olverembatinib in chronic myelogenous leukemia (CML), sponsored by Shunjian Biopharmaceutical. Started Oct 2019; status: completed.
02
Drugs
olverembatinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on CTR20191420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191420.